Press release - 01/07/2026 Newly Discovered Marker for Metastatic Colorectal Cancer Is the Achilles’ Heel of Highly Aggressive Tumor Cells A team led by researchers from the German Cancer Research Center and the HI-STEM* Stem Cell Institute has discovered a new approach to treating advanced colorectal cancer. The study identifies a key marker of particularly aggressive and treatment-resistant colorectal cancer cells. At the same time, the researchers demonstrate using models that already approved drugs targeting this marker can specifically attack the metastasis-initiating cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-marker-metastatic-colorectal-cancer-achilles-heel-highly-aggressive-tumor-cells
Press release - 29/07/2026 ERC Synergy Grant has started The international research project MitoContact is dedicated to investigating how organelles within a cell communicate and interact with other cellular components. Kai Johnsson, Director at the Max Planck Institute for Medical Research, has received funding from the ERC for this project. The findings are expected to provide new insights into fundamental cellular processes and contribute to a better understanding of various diseases. https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-synergy-grant-has-started
Press release - 09/07/2025 A new drug target for treating cancer and viral infections An international team of researchers led by Konstanz biologists has identified a molecular mechanism that regulates the activity of N-myristoyltransferases. This enzyme plays a role in biological signalling pathways, where dysregulation can lead to serious illness.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-drug-target-treating-cancer-and-viral-infections
Press release - 07/05/2026 MRI is a better indicator than BMI of when body fat becomes dangerous MRI analysis of fat and muscle distribution in more than 66,000 people provides a more accurate assessment of health risks / Poor muscle quality poses an additional risk / Study provides reference values based on age, sex, and heighthttps://www.gesundheitsindustrie-bw.de/en/article/press-release/mri-better-indicator-bmi-when-body-fat-becomes-dangerous
Press release - 04/09/2024 Epigenetic changes reprogram astrocytes into brain stem cells With mice, researchers showed that experimentally induced lack of blood flow in the brain epigenetically reprograms astrocytes into brain stem cells, which in turn can give rise to nerve progenitor cells. This discovery shows that astrocytes could potentially be used in regenerative medicine to replace damaged nerve cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetic-changes-reprogram-astrocytes-brain-stem-cells
Computer tool opens up new ways to address antibiotic resistance - 02/07/2025 PhARIS identifies effective phages against multi-resistant bacteria Bacteriophages - viruses that specifically attack and destroy bacteria - are emerging as promising alternatives to antibiotics in the fight against drug-resistant infections. To speed this effort, researchers have created PhARIS, a computational tool that mines genomic data to pinpoint phages that are effective against S. aureus. By rapidly matching phage and pathogen, PhARIS can accelerate the development of targeted phage therapies.https://www.gesundheitsindustrie-bw.de/en/article/news/pharis-identifies-effective-phages-against-multi-resistant-bacteria
Press release - 17/02/2025 Pancreatic cancer: blocked nerves as a possible new treatment strategy Pancreatic cancer is fueled by connections to the nervous system. This is reported by scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)*. The team discovered that the tumor reprograms the neurons for its own benefit. https://www.gesundheitsindustrie-bw.de/en/article/press-release/pancreatic-cancer-blocked-nerves-possible-new-treatment-strategy
Press release - 09/07/2025 The evolution of cancer cells decoded Cancer can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Center have now developed a method that allows for the first time to reconstruct the temporal development—the evolution—of cancerous cells from a single tissue sample. https://www.gesundheitsindustrie-bw.de/en/article/press-release/evolution-cancer-cells-decoded
Press release - 31/07/2026 A new genetic tool helps researchers uncover the logic of gene regulation Researchers use synthetic biology approaches to test hundreds of DNA sequences for their effect on regulating gene expression. The human genome contains over 20,000 genes. However, at any given time and in a given cell, only a fraction of them are active. Researchers from EMBL Heidelberg’s Krebs Group have come up with an innovative experimental approach to understand how cells determine which genes to turn on and when.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-genetic-tool-helps-researchers-uncover-logic-gene-regulation
Vaccine development - 25/05/2021 Vaccines - a beacon of hope in the fight against pandemics Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
SICOS BW GmbH - 18/06/2020 High-performance computing and data analytics to combat coronavirus In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.https://www.gesundheitsindustrie-bw.de/en/article/news/high-performance-computing-and-data-analytics-to-combat-coronavirus
Press release - 12/05/2022 New imaging method makes tiny medical robots visible in the body Microrobots have the potential to revolutionize medicine. Researchers at the Max Planck ETH Centre for Learning Systems have now developed an imaging technique that for the first time recognises cell-sized microrobots individually and at high resolution in a living organism. This is an important step towards precise control of the robots and their clinical translation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-imaging-method-makes-tiny-medical-robots-visible-body
Press release - 09/11/2022 New Molecular Microscopy Uncovers how Breast Cancer Spreads Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-microscopy-uncovers-how-breast-cancer-spreads
Press release - 17/09/2025 AI model predicts disease risks decades in advance Scientists from the European Molecular Biology Laboratory (EMBL) and the German Cancer Research Center (DKFZ) have developed an AI model that assesses the long-term individual risk for more than 1,000 diseases. The model, which was trained and tested using anonymized medical data from the UK and Denmark, can predict health events over a period of more than a decade.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-model-predicts-disease-risks-decades-advance
Press release - 22/03/2024 Decoding the shared genetic toolkit for male sex determination Researchers from the Max Planck Institute for Biology Tübingen broke new ground by demonstrating that an HMG-box gene in brown algae is crucial for determining male sex. This breakthrough significantly expands our understanding of sex-determination mechanisms in eukaryotic organisms. Until now, master sex-determination genes had been identified in only a select number of animals and plants. https://www.gesundheitsindustrie-bw.de/en/article/press-release/decoding-shared-genetic-toolkit-male-sex-determination
Press release - 21/05/2025 How aging changes the blood system in humans and mice The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. The new discovery could help explain the chronic inflammation that occurs with age and makes us more susceptible to disease. It could also help identify early warning signs of unhealthy aging processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-aging-changes-blood-system-humans-and-mice
Press release - 03/03/2026 AI Chip Design From Heilbronn AI plays a huge role in the semiconductor industry, both by facilitating more efficient development processes and as a target application in development work. This is why the Fraunhofer Heilbronn Research and Innovation Centers HNFIZ are adding the Chip AI research and innovation center for AI chip design to their service range. The center is funded via the Dieter Schwarz Foundation. https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-chip-design-heilbronn
Press release - 11/06/2026 VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026 VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, today announced that its previously announced business combination (“Business Combination”) with Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, was closed successfully (the “Closing”)https://www.gesundheitsindustrie-bw.de/en/article/press-release/veraxa-biotech-debut-publicly-traded-company-pioneering-next-generation-cancer-therapies-june-11-2026
Article - 14/04/2021 Calling for quality seal for implants Today's seniors are older and more active, which is why implants remain in the body longer and are subjected to greater strain than before. Improved surfaces are expected to ensure that the implants heal and integrate into the bone optimally. In an interview with BIOPRO, Dietmar Schaffarczyk, CEO of Konstanz-based stimOS GmbH, explains why a voluntary quality seal makes sense and gives consumers a better chance of recognising high-quality…https://www.gesundheitsindustrie-bw.de/en/article/news/calling-quality-seal-implants
Press release - 18/12/2021 WHO publishes first classification of childhood tumors The International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO), will soon publish the first edition of its classification of childhood cancers. The new WHO classification forms the basis of modern, precise cancer diagnostics for physicians and pediatric oncologists worldwide and is based on the latest international research findings.https://www.gesundheitsindustrie-bw.de/en/article/press-release/who-publishes-first-classification-childhood-tumors
Press release - 17/11/2022 MEDICA and COMPAMED present themselves as extremely vital platforms in turbulent times MEDICA and COMPAMED continue to develop in an extremely vital manner. The world's leading medical trade fair and the international No. 1 for the medical technology supply sector once again impressively underscored their positive results from the previous year with strong numbers – despite continuing adverse conditions. A significant increase in bookings on the part of the exhibiting companies was followed after four days by a marked increase…https://www.gesundheitsindustrie-bw.de/en/article/press-release/medica-und-compamed-praesentieren-sich-als-aeusserst-vitale-plattformen-bewegten-zeiten
Press release - 10/04/2024 Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
Press release - 05/09/2025 After EMBL: Umlaut.bio and its potential role in drug development Alumnus Bastian Linder discusses the origin of this start-up and how a tRNA mechanism is helping scientists understand the importance and use of various RNA modifications as they pertain to disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/after-embl-umlautbio-and-its-potential-role-drug-development
Dossier - 18/06/2012 Biobanks treasure chests for biomedical research The Research Committee at the German Bundestag, the Office of Technology Assessment at the German Bundestag and the German Ethics Council are all interested in this biomedical research tool, which is both necessary and meaningful. However, opinions with regard to the ethical, legal and technical approach to biobanks differ. Since March 2012 it has become absolutely clear that Germany will not pass a biobanking law during the current mandate. https://www.gesundheitsindustrie-bw.de/en/article/dossier/biobanks-treasure-chests-for-biomedical-research